A recent review from a gynaecology oncology clinic in Malaysia reports that patients with advanced and recurrent ovarian cancer who were properly guided and incorporate an integrative medicine approach early which included intravenous vitamin C as a tool lived longer. Such approaches were used either alone and monitored and also together with surgery and / or chemotherapy as needed. Integrative medicine was a foundational element throughout care (i.e. diet, life style, natural medicine, supplements, meditation, etc.). The patients who only used chemotherapy (and without an integrative approach) did not live as long. While this work is preliminary, retrospective, and it lacked a comparative group it mirrors what we have seen in clinical practice with patients with ovarian cancer as well here in Vancouver. It was also interesting to note that the case series obtained publication approval from Director General of Health, Ministry of Health, Malaysia. Other government groups here in Canada should follow.
The injectable use of mistletoe, which includes the application inside the abdomen via drain tube, leads to long-term survival in a platinum-resistant ovarian cancer case report.
Follow the below link for the published case details.
Respected Canadian cancer journal Current Oncology acknowledges and publishes article by the Oncology Association of Naturopathic Physicians on recommended guidelines for the role of naturopathic medicine applied to people with cancer. Well done!! To learn more about the article, it can be found below.
NEW – Intravenous Vitamin C – A Collaborative Article Between Oncologists and Naturopathic Physicians Working Together
New research on the practical use of Intravenous Vitamin C (IVC) in cancer from medical oncologists and naturopathic physicians working together which also includes discussions on how to use along with chemotherapy. The lower dosing guidelines as suggested in this article have been long supported in our clinical experiences as well.
Recently a study published in JAMA Oncology demonstrated that the addition of regional hyperthermia to chemotherapy improved survival in patients with high-risk soft tissue sarcoma cancers.
Median local progression-free survival was 67.3 months in the hyperthermia group vs 29.2 months in the group without. Median disease-free survival was 33.3 months in the hyperthermia group vs 17.4 without. Median overall survival was 15.4 years with hyperthermia vs 6.2 years without, with 5-year survival rates of 62.7% vs 51.3% and 10-year survival rates of 52.6% vs 42.7%.
The use of hyperthermia or high temperature heating should be further explored in this area. Furthermore as the authors mention, “we should not exclude the potential therapeutic benefits regional hyperthermia may also have in solid tumors other than soft tissue sarcoma.”
We have noticed there are population groups where the addition of this technology appears to enhance not only chemotherapy, radiation, and even immunotherapy treatment approaches with several cancer types.
Please follow the below link to learn more about this interesting new article.
The use of mistletoe in cancer is a popular treatment in cancer in many European countries. The common use is by injection given under the skin and there is a growing interest in the intravenous application. I would classify mistletoe as an original “immune-system” treatment that has finally become to the attention of the mainstream oncology community. Clinically we have seen patients with cancer respond to this form of treatment by improving quality of life symptoms such as in pain, appetite, and energy. Furthermore, there are groups where we have documented a cancer-fighting effect. The first patient we personally treated over 10 years ago was with advanced and progressing colon cancer, where the intravenous application of mistletoe stabilized his disease outside of any chemotherapy treatment. This experience opened our minds to the capabilities of this promising therapy.
The below recent study discusses the application and experience of mistletoe given by intravenous treatment to patients with cancer by a group of European physicians. Positive benefits were noted which included cases of patients whose disease was better controlled and more.
To find out more, please follow the below link.
Fasting for up to 72 h, divided as 48 h before and 24 h after chemotherapy infusion, appears safe and feasible in people with cancer receiving platinum-based combination chemotherapy. Preliminary evidence from correlative studies supports that fasting may protect the body and tissues against chemotherapy damage.
Subjects were instructed to consume zero calories, but ample water and non-caloric beverages. However subjects were advised that if they had symptoms related to fasting (such as feeling faint, weak, dizzy, etc.) that they should consume a small amount of juice or food, aiming to stay under 200 kcal in a 24 h period.
The scientific journal article can be found below for further information.
In Prostate Cancer, substituting 30 g/day of poultry or fish for total or unprocessed red meat was associated with significantly lower risk of recurrence. Lower intakes of red meat and well-done red meat and higher intakes of poultry and fish are associated with lower risk of high grade and advanced prostate cancer and reduced recurrence risk, independent of stage and grade.
See the published article below:
We are excited and proud of Sarina Auriel’s new book The HeartFull Way, a step-by-step guide to moving from surviving to thriving. Her program is a gentle and empowering practice for creating healing in individuals, in families and across generations. Following The HeartFull Way it is possible to transform a full life into a life lived fully and from the heart.
Please join the book launch event at the beautiful new Wesbrook Community Centre (UBC) on Thursday, October 20, 2016 from 7 to 9 pm
Please see the below link for further information.
Dr Lemmo’s case report is a leading story in this months Integrative Cancer Therapies journal. It is an honour to have Dr. Keith Block, a respected and pioneering oncologist, comment on our Raloxifene Anti-Estrogen Withdrawal Effect case which was published online in July 2016. In this issue you will also see the more detailed Editorial by Dr. V. Craig Jordan, also known as the “Father of Tamoxifen”, from MD Anderson Cancer Center regarding this case report and his fascinating insights into how a women’s own estrogen can shrink breast cancer even when followed by hormone treatments such as Tamoxifen and related drugs.
Please see the below link to read Dr. Keith Block’s Editorial.